Presentations on ABIOMED’s Heart Recovery Technology, including the IMPELLA® RECOVER LP 2.5, the world’s smallest micro-Ventricular Assist Device (VAD) will include:

• On Wednesday, May 17, ABIOMED will host a symposium on “Percutaneous Mechanical Support in High Risk PCI & Cardiogenic Shock, IMPELLA – Your Safety Net in the Cath Lab.” The event starts at 4:30 pm in the Palais des Congres, level 3, room 322/323.
• On Thursday, May 18, Dr. J.P.S. Henriques, Cardiologist at the Academic Medical Center in Amsterdam, will present on “Left Main Stenting with IMPELLA RECOVER 2.5 LP Supporting Poor LV Patients,” in room 251 at 8:30 am.
• Also on Thursday, May 18, Dr. Patrick Hunziker, Cardiologist at the University of Basel in Switzerland, will present on “Where is the ‘Point of No Return’ in PCI for Acute Myocardial Infarction with CPR?” in room 251 at 3:10 pm.

ABIOMED’s IMPELLA RECOVER Technology consists of the IMPELLA Recover® LP 2.5, the IMPELLA Recover® 5.0, the IMPELLA Recover ® RD, and the IMPELLA Recover ® LD which are available in Europe under the CE Mark and are investigational in the United States. This technology has been the subject of more than 20 peer reviewed international publications. The Recover® LP 2.5 provides interventional cardiologists with a minimally invasive ventricular unloading catheter, which is inserted percutaneously via the femoral artery into the left ventricle.

ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA® RECOVER® minimally invasive cardiovascular support systems under CE Mark approval. The IMPELLA products are not yet available for sale in the United States. The Company’s AbioCor® Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: www.abiomed.com.

Contacts:
Liza Heapes
ABIOMED, INC.
Media Relations
(978) 646-1668
mediarelations@abiomed.com

Daniel Sutherby
ABIOMED, INC.
Chief Financial Officer
(978) 646-1812
ir@abiomed.com

FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of ABIOMED’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

###